HE8
0.002
100%
KNI
0.02
-25.9%
COY
0.005
66.7%
SNT
0.027
-22.9%
BSN
0.033
50%
ARF
2.56
-22%
OVT
0.003
50%
ITS
0.21
-20.8%
TMX
0.003
50%
SLM
0.068
-20%
WOA
0.014
40%
HCT
0.055
-17.9%
RIM
0.015
36.4%
BNL
0.005
-16.7%
ARO
0.004
33.3%
CLA
0.005
-16.7%
BET
0.22
33.3%
FCT
0.005
-16.7%
BLU
0.004
33.3%
H3E
0.005
-16.7%
PER
0.004
33.3%
REE
0.01
-16.7%
AVH
2.03
31.8%
YAR
0.005
-16.7%
EVG
0.028
27.3%
JAT
0.11
-15.4%
FRE
0.033
26.9%
PKO
0.006
-14.3%
FLN
0.145
26.1%
XRA
0.19
-13.6%
ENL
0.005
25%
MDI
0.013
-13.3%
L1M
0.015
25%
CNJ
0.007
-12.5%
HMI
0.034
21.4%
T92
0.038
-11.6%
RB6
0.115
21.1%
ATT
0.008
-11.1%
PHO
0.145
20.8%
DUB
0.008
-11.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Neuren Pharmaceuticals Limited (ASX:NEU): Reports top-line results from its Phase 2 clinical trial

Neuren Pharmaceuticals Limited (ASX:NEU) has reported top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Angelman syndrome.

🩺 Clinician and caregiver global efficacy measures specifically designed for Angelman syndrome showed a level of improvement
💊 NNZ-2591 was safe and well tolerated as an oral liquid dose, with no serious adverse events
⚕️Results further strengthen confidence in potential of NNZ-2591 for multiple neurodevelopmental disorders

ASX announcement ⚡ https://announcements.asx.com.au/asxpdf/20240809/pdf/066gd3hmzlyp3z.pdf Jon Pilcher